





10/01/91 90

FIGURE 1FIGURE 2

BEST AVAILABLE COPY

FIGURE 3FIGURE 4

h4g human eIF4G B β KKRYDREFLLGFAARQIKIWFQNRRMKWKK


S scrambled eIF4G B β FDLKFALGRYRAEKRQIKIWFQNRRMKWKK

no peptide

rec 4E recombinant human eIF4E


FIGURE 5

H	human eIF4G	B β β K K R <u>Y</u> D R E F <u>L L</u> G F 413-424
Y	yeast eIF4G	B β β K Y T <u>Y</u> G P T F <u>L L</u> Q F 449-460
W	wheat eIF4G	B β β R V R <u>Y</u> S R D Q <u>L L</u> D L 62-73
1	human 4E-BP1	B β β R I I <u>Y</u> D R K F <u>L</u> M E U 51-62
2	human 4E-BP2	B β β R I I <u>Y</u> D R K F <u>L L</u> D R 51-62
S	scrambled eIF4G	

FIGURE 6



<u>4G Peptide</u>		<u>Sequence</u>
H _{wt}	hu 4G ₍₄₁₃₋₄₂₄₎	K K R <u>Y</u> D R E F <u>L L</u> G F A A
H _{3A}	hu 4G _{(413-424)YALALA}	K K R A D R E F A A G F A A
W _{wt}	wh 4G ₍₆₂₋₇₃₎	R V R <u>Y</u> S R D Q <u>L L</u> D L A A
W _{3A}	wh 4G _{(62-73)YALALA}	R V R A S R D Q A A D L A A
S	scrambled hu 4G	F D L K F A L G R Y R A E K

all peptides biotinylated and linked to Penetratin™


FIGURE 7FIGURE 8

Peptide	Concentration			
	3 μ M	6 μ M	9 μ M	12 μ M
hu 4G ₍₄₁₃₋₄₂₄₎	+	++	+++	+++
hu 4G _{(413-424)Y416AL421AL422A}	-	-	-	-
wh 4G ₍₆₂₋₇₃₎	-/+	+	++	+++
wh 4G _{(62-73)Y65AL70AL71A}	-	-	-	-
scrambled hu 4G	-	-	-	-

MRC5 cells, 72 h serum-free growth, all peptides biotinylated and linked to Penetratin™

FIGURE 9FIGURE 10

6/12

FIGURE 11

7/12

FIGURE 12

(a)

Hu 4G	Human eIF4G Peptide (569-580) Wild Type	KKRYDREF <u>FL</u> LG
Hu 4G YLL-AAA	Human eIF4G Peptide (569-580)Y572A L577A L578A	KKRADREF <u>A</u> AGF
Hu 4G Y-A	Human eIF4G Peptide (569-580)Y572A	KKRADREF <u>FL</u> GF
Hu 4G L-A	Human eIF4G Peptide (569-580)L577A	KKRYDREF <u>AL</u> GF
W4G	Wheat eIF4G Peptide (62-73) Wild Type	RVRYSRD <u>Q</u> LLDL
W4G YLL-AAA	Wheat eIF4G Peptide (62-73)Y65A, L70A, L71A	RVRASRD <u>Q</u> AADL
BP2	Human 4E-BP2 Peptide (51-62) Wild Type	RIIYDRKF <u>LL</u> DR
BP2 YLL-AAA	Human 4E-BP2 Peptide (51-62)Y54A, L59A, L60A.	RIIADRKF <u>AA</u> DR
BP1	Human 4E-BP1 Peptide (51-62) Wild Type	RIIYDRKF <u>L</u> MEU
BP1 YLM-AAA	Human 4E-BP1 Peptide (51-62)Y54A, L59A, M60A	RIIADRKF <u>AA</u> EU

(b)






FIGURE 13


(a)



(b)



(c)



(d)





FIGURE 14

1001998-061902 3

10/12

FIGURE 15




FIGURE 16

(a)





FIGURE 16 (cont.)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.